Enhancing the efficacy of hormonal agents with selected targeted agents

Clinical Breast Cancer

Volumn 9, Issue SUPPL.1, 2009, Pages

  Johnston, Stephen R D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Estrogen receptor; Fulvestrant; Gefitinib; Growth factor; Signaling blockade; Tamoxifen

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; FULVESTRANT; GEFITINIB; IMATINIB; LAPATINIB; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE; SORAFENIB; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UO 126; VATALANIB; VORINOSTAT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; PROTEIN KINASE INHIBITOR;

BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; BREAST TUMOR; DRUG RESISTANCE; FEMALE; METABOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTORS, ESTROGEN;

EID: 70249128382     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.s.003     Document Type: Article

References (71)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
2. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58.
3. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12.
4. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22.
5. Encarnación CA, Ciocca DR, McGuire WL, et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993;26:237-46.
6. Johnston SR, Saccani-Jotti G, Smith IE, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995;55:3331-8.
7. Johnston SR, Lu B, Dowsett M, et al. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res 1997;57:3723-7.
8. Kuukasjärvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-9.
9. Petz LN, Ziegler YS, Schultz JR, et al. Fos and Jun. inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 2004;18:521-32.
10. Ferguson AT, Lapidus RG, Baylin SB, et al. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995;55:2279-83.
11. Creighton CJ, Hilger AM, Murthy S, et al. Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors. Cancer Res 2006;66:3903-11.
12. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
13. Munzone E, Curigliano G, Rocca A, et al. Reverting estrogen-receptor- negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy [published erratum in: Breast Cancer Res 2006;8:407].
14. Breast Cancer Res 2006;8:R4
15. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006;103:7795-800.
16. Masamura S, Santner SJ, Heitjan D F, et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25.
17. Martin L-A, Farmer I, Johnston SRD, et al. Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458-68.
18. Santen R, Jeng MH, Wang J P, et al. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001;79:115-25.
19. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
20. Chen D, Washbrook E, Sarwar N, et al. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002;21:4921-31.
21. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
22. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
23. Fan P, Wang J, Santen RJ, et al. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor α out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 2007;67:1352-60.
24. Leary A F, Martin L-A, Lykkesfeldt AE, et al. Lapatinib can activate or supress estrogen receptor (ER) signaling in cell models of endocrine resistant breast cancer. Cancer Res 2009;69(suppl) :218s (abstract 3031).
25. Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032-44.
26. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68:826-33.
27. Martin L-A, Pancholi S, Chan CM, et al. The anti-oestrogen ICI 182, 780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005;12:1017-36.
28. Jeng MH, Yue W, Eischeid A, et al. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res Treat 2000;62:167-75.
29. Gee JM, Harper ME, Hutcheson IR, et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in Vitro. Endocrinology 2003;144:5105-17.
30. Kurokawa H, Lenferink AE, Simpson J F, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
31. Pancholi S, Lykkesfeldt AE, Hilmi C, et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen resistant MCF-7 cells leading to activation of AKT and RPS6KA2. Endocr Rel Cancer 2008;15:985-1002.
32. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377-88.
33. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-50.
34. Perey L, Paridaens R, Hawle H, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research trial (SAKK 21/00). Ann Oncol 2007;18:64-9.
35. Steger GG, Bartsch R, Wenzel C, et al. Fulvestrant in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 2005;41:2655-61.
36. Ingle JN, Suman VJ, Rowland KM, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group trial N0032. J Clin Oncol 2006;24:1052-6.
37. Chia S, Gradishar WJ, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-70.
38. Osipo C, Gajdos C, Liu H, et al. Paradoxical action of fulvestrant in estradiolinduced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003;95:1597-608.
39. Jelovac D, Macedo L, Goloubeva OG, et al. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005;65:5439-44.
40. Macedo L F, Sabnis GJ, Goloubeva OG, et al. Combination of anastrozole with fulvestrant in the intrautumoral aromatase xenograft model. Cancer Res 2008;68:3516-22.
41. Johnston SR, Leary A, Martin L-A, et al. Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise? Cancer 2008;112:710-7.
42. Albain K, Elledge R, Gradishar WJ, et al. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S33 (abstract 20).
43. Baselga J, Albanell J, Ruiz A, et al. Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer. J Clin Oncol 2005;23:5323-33.
44. Robertson J F, Gutteridge E, Cheung KL, et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol 2003;22:7 (abstract 23).
45. Guix M, de Matos Granja N, Meszoely I, et al. Short preoperative treatment with erlotinib inhibits tumour cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 2008;26:897-906.
46. Mita M, Bono J, Mita A. A phase II and biologic correlative study investigating anastrozole (A) in combination with gefitinib (G) in postmenopausal patients with estrogen receptor positive (ER) metastatic breast carcinoma (MBC) who have previously failed hormonal therapy. Breast Cancer Res Treat 2005;94(suppl 1):S80 (abstract 1117).
47. Mayer I, Ganja N, Shyr Y, et al. A phase II trial of letrozole plus erlotinib in post-menopausal women with hormone-sensitive metastatic breast cancer (MBC) : preliminary results of toxicities and correlative studies. Breast Cancer Res Treat 2006;100(suppl 1):S189 (abstract 4052).
48. Smith IE, Walsh G, Skene A, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007;25:3816-22.
49. Polychronis A, Sinnet HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial [published erratum in: Lancet Oncol 2005;6:357].
50. Lancet Oncol 2005;6:383-91.
51. Atkins D, Reiffen K-A, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity resulting from the choice of fixative and the length of storage time. J Histochem Cytochem 2004;52:893-901.
52. Osborne K, Neven P, Dirix L, et al. Randomized phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 2007;106(suppl 1):S107 (abstract 2067).
53. Cristofanilli M, Valero V, Mangalik A, et al. A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol 2008;26(suppl) :44S (abstract 1012).
54. Valero V, Bacus S, Mangalik A, et al. Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Res 2009;69(suppl) :246s (abstract 3131).
55. Oh AS, Lorant LA, Holloway JN, et al. Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol Endocrinol 2001;15:1344-59.
56. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43-9.
57. Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progressionfree survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006;100(suppl 1):S5 (abstract 3).
58. Leary A F, Martin LA, Lykkesfeldt, AE, et al. Enhancing endocrine responsiveness using the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in cell models of endocrine resistance. Breast Cancer Res Treat 2006;100(suppl 1):S29 (abstract 303).
59. Chu I, Blackwell K, Chen S, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18-25.
60. Johnston S, Pegram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for frontline postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC) : first results from the EGF30008 trial. Cancer Res 2009;69(suppl) :74s (abstract 46).
61. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995;35:133-44.
62. Martin L-A, Head JE, Pancholi S, et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther 2007;6:2458-67.
63. Johnston SR, Semiglazov V F, Manikhas GM, et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2008;110:327-325.
64. Wu G, Xing M, Mambo E, et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005;7:R609-16.
65. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers [published erratum in Cancer Biol Ther 2005;4:133].
66. Cancer Biol Ther 2004;3:772-5.
67. Baselga J, Roché H, Fumoleau P, et al. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study. Breast Cancer Res Treat 2005;94(suppl 1):S62 (abstract 1068).
68. Chow LW, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006;100(suppl 1):S286 (abstract 6091).
69. Clinicaltrials.gov [Web site]. Available at: http://www.clinicaltrials. gov. Accessed: May 15, 2009.
70. Baselga J, Semiglazov V, van Dam P, et al. Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER+ breast cancer. Breast Cancer Res Treat 2007;106(suppl 1):S107 (abstract 2066).
71. Gardner H, Bandaru R, Barret C, et al. Biomarker analysis of a phase II doubleblind randomised trial of daily oral RAD001 (everolimus) plus letrozole or placebo plus letrozole as neoadjuvant therapy for patients with estrogen receptor positive breast cancer. Breast Cancer Res Treat 2007;106(suppl 1):S167 (abstract 4006).